Abstract CT130: Molecular-biological tumor profiling for drug treatment selection in patients with advanced and refractory carcinoma: A prospective, two-stage Phase II individualized cancer treatment study
Samantha Perakis(Medical University of Graz), Armin Gerger(Medical University of Graz), Karl Kashofer(Medical University of Graz), Lukas Scheipner(Medical University of Graz), Jakob M. Riedl(Medical University of Graz), Michael R. Speicher(Medical University of Graz), Ellen Heitzer(Medical University of Graz), Gerald Höefler(Medical University of Graz), Jochen B. Geigl(Medical University of Graz), Peter Ulz(Freenome (United States))
Cited by 0
Related Papers
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
|Immunity|2013|4.7k
Mutations in <i>GNA11</i> in Uveal Melanoma
|New England Journal of Medicine|2010|1.5k
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability
|Immunity|2016|1.1k
Cognitive impairment by antibiotic-induced gut dysbiosis: Analysis of gut microbiota-brain communication
|Brain Behavior and Immunity|2016|741
Germline mutations in BAP1 predispose to melanocytic tumors
|Nature Genetics|2011|724